课题基金 / 基金详情

R&D-OTHER R & D-A RES/EXPL DEV

R&D-OTHER R & D-A RES/EXPL DEV
右
批准号:
7952669
负责人:
ETHAN M. BASCH
金额:
$104.98万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-30 至 2010-09-29
关键词:

项目摘要

项目成果

ETHAN M. BASCH的其他基金

相似基金

相关文献

中文摘要
翻译
承包商应制定患者报告的症状要素结局版本, 不良事件通用术语标准(PRO-CTCAE)。这个系统将收集癌症患者的 对有关其健康状况、症状、功能和健康相关生活质量的问题的回答, NCI不良事件报告系统中的信息。 承包商应编制一份详细的文件,确定障碍、理想条件和实施方案 PRO-CTCAE,开发与CTCAE完全集成的PRO-CTCAE评估软件系统, 评估新PRO-CTCAE的有效性、可靠性、可行性和临床效用的研究,并创建培训 支持PRO-CTCAE的教育材料。
英文摘要
The Contractor shall develop the Patient-Reported Outcomes version of symptom elements that are contained within the Common Terminology Criteria for Adverse Events (PRO-CTCAE). This system will collect cancer patients' responses to questions about their health status, symptoms, functioning and health-related quality of life and integrate this information within the NCI adverse event reporting system. The Contractor shall produce a detailed document that identifies barriers, ideal conditions, and solutions to implement the PRO-CTCAE, develop the PRO-CTCAE assessment software system fully integrated with the CTCAE, conduct studies to evaluate the validity, reliability, feasibility and clinical utility of the new PRO-CTCAE, and create Training and Educational Materials to Support the PRO-CTCAE.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug Tolerability
国内基金
海外基金
腊状芽胞杆菌ATCC 14579中赖氨酰tRNA合成酶I(LysRS1)和tRNA-Other的生理功能研究
  • 批准号:
    30770034
  • 项目类别:
    面上项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2007
  • 负责人:
    王世明
  • 依托单位: